Download from app store
We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.

Journal Scan / Research · April 06, 2022

Dalpiciclib Combined With Pyrotinib and Letrozole in Women With HER2–Positive, HR–Positive Metastatic Breast Cancer

Frontiers in Oncology


Additional Info

Frontiers in Oncology
Dalpiciclib Combined With Pyrotinib and Letrozole in Women With HER2-Positive, Hormone Receptor-Positive Metastatic Breast Cancer (LORDSHIPS): A Phase Ib Study
Front Oncol 2022 Mar 07;12(xx)775081, J Zhang, Y Meng, B Wang, L Wang, J Cao, Z Tao, T Li, W Yao, X Hu

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Further Reading